Studying DNA Changes in Lung Cancer Tissue and Blood Samples
This study is looking at tumor tissue and blood samples from people with lung cancer to understand changes in their DNA. Researchers want to learn more about a specific pathway called EGFR (Epidermal Growth Factor Receptor) and how mutations (changes) in this pathway relate to how patients do over time. You can join if you are 18 or older and have lung cancer that has been confirmed by a doctor. You may have already received treatments for EGFR. The study aims to enroll 800 participants. The current recruitment status is unclear.
- Study design
- This is an observational study, meaning researchers will collect and analyze samples without giving new treatments. It plans to include 800 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The mutational status of the EGFR pathway will be measured for up to 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jonathan Riess, MD · PRINCIPAL_INVESTIGATOR · University of California, Davis
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Mutational status of the EGFR pathwayup to 1 year